Details for Patent: 9,549,909

Which drugs does patent 9,549,909 protect, and when does it expire?

Patent 9,549,909 protects FINTEPLA and is included in one NDA.

Protection for FINTEPLA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-nine patent family members in sixteen countries.

Summary for Patent: 9,549,909

Patent landscape, scope, and claims:

Title:	Method for the treatment of dravet syndrome
Abstract:	A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.
Inventor(s):	Ceulemens; Berten (Leuven, BE), Lagae; Lieven (Edegem, BE)
Assignee:	The Katholieke Universiteit Leuven (Leuven, BE) University Hospital Antwerp (Edegem, BE)
Application Number:	13/887,014
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 9,549,909

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ucb Inc	FINTEPLA	fenfluramine hydrochloride	SOLUTION;ORAL	212102-001	Jun 25, 2020		RX	Yes	Yes	9,549,909*PED				Y

International Family Members for US Patent 9,549,909

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014261329
Australia	2019203448
Australia	2019203832
Australia	2020267264
Brazil	112015027282
Canada	2909335
Cyprus	1124298